Comment on “Biomarkers as Potential Treatment Targets in Inflammatory Bowel Disease: A Systematic Review”

Comment on “Biomarkers as Potential Treatment Targets in Inflammatory Bowel Disease: A Systematic Review”

Saved in:

Bibliographic Details
Main Authors:	Nicholas-Paul Delicata, Neville Azzopardi, Pierre Ellul
Format:	Article
Language:	English
Published:	Wiley 2016-01-01
Series:	Canadian Journal of Gastroenterology and Hepatology
Online Access:	http://dx.doi.org/10.1155/2016/3238925
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Novel Biomarkers and the Future Potential of Biomarkers in Inflammatory Bowel Disease
by: Gilles Duvoisin, et al.
Published: (2017-01-01)

Metallothioneins in Inflammatory Bowel Diseases: Importance in Pathogenesis and Potential Therapy Target
by: Anna Socha-Banasiak, et al.
Published: (2021-01-01)

Comment on “Prevalence of Anxiety and Depression in Patients with Inflammatory Bowel Disease”
by: Wenwen Lai, et al.
Published: (2018-01-01)

Novel Targets for Anti-Inflammatory Therapy in Inflammatory Bowel Disease
by: John L Wallace
Published: (1994-01-01)

Treatment of Inflammatory Bowel Disease in Children
by: D Grant Gall
Published: (1990-01-01)

Worms and the Treatment of Inflammatory Bowel Disease: Are Molecules the Answer?
by: Tom G. Moreels, et al.
Published: (2008-01-01)

Biomarkers in Inflammatory Bowel Disease-Associated Spondyloarthritis: State of the Art and Unmet Needs
by: Devis Benfaremo, et al.
Published: (2019-01-01)

The Influence of Non-Hfe Genes and Steatohepatitis on Increased Iron Stores in Patients with the H63D Mutation
by: Neville Azzopardi
Published: (2015-01-01)

Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease
by: Tetsuhiro Yoshimura, et al.
Published: (2021-01-01)

Immunosuppressants in modern approaches to treatment of inflammatory bowel diseases
by: O. B. Schukina, et al.
Published: (2013-05-01)

Evidence for a Potential Role of Metallothioneins in Inflammatory Bowel Diseases
by: Anouk Waeytens, et al.
Published: (2009-01-01)

Resveratrol and its derivates improve inflammatory bowel disease by targeting gut microbiota and inflammatory signaling pathways
by: Ming Li, et al.
Published: (2022-01-01)

Iron deficiency and fatigue in inflammatory bowel disease: A systematic review.
by: Stephanie Sartain, et al.
Published: (2025-01-01)

The exercise-induced inflammatory response in inflammatory bowel disease: A systematic review and meta-analysis.
by: Kelly A Baker, et al.
Published: (2022-01-01)

Contrasting Psychotherapeutic Treatments in Inflammatory Bowel Disease: an Exploratory Review
by: Carlos Enrique Zerpa
Published: (2024-05-01)

Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments
by: Bruno Rafael Ramos de Mattos, et al.
Published: (2015-01-01)

Dysplasia in Inflammatory Bowel Diseases: Definition and Clinical Impact
by: Karel Geboes, et al.
Published: (1999-01-01)

Immunopathogenesis of inflammatory bowel diseases
by: Ye. A. Konovich, et al.
Published: (2013-09-01)

Inflammatory Bowel Disease and Statins
by: V. V. Genkel, et al.
Published: (2020-04-01)

Somatostatin in inflammatory bowel disease
by: J. D. Van Bergeijk, et al.
Published: (1997-01-01)

Exercise and Inflammatory Bowel Disease
by: Neeraj Narula, et al.
Published: (2008-01-01)

Autoimmunity in Inflammatory Bowel Disease
by: Kiron M Das
Published: (1993-01-01)

Cytokines in inflammatory bowel disease
by: P. L. Beck, et al.
Published: (1997-01-01)

Advances in Inflammatory Bowel Disease: Are Patients Taking Their Medicines?
by: Subrata Ghosh, et al.
Published: (2009-01-01)

Therapeutic potential and mechanism of functional oligosaccharides in inflammatory bowel disease: a review
by: Xiaochun Yang, et al.
Published: (2023-11-01)

Prospects of Using Microbiota Correction Methods in the Treatment of Inflammatory Bowel Disease
by: A. I. Akinshina, et al.
Published: (2019-05-01)

The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease
by: P. Rutgeerts
Published: (1998-01-01)

Clinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel disease
by: Ronghui Li, et al.
Published: (2025-01-01)

Nonsteroidal Anti-Inflammatory Drugs and Inflammatory Bowel Disease
by: Ingvar Bjarnason, et al.
Published: (1993-01-01)

Mesalazine-Induced Acute Pancreatitis in Inflammatory Bowel Disease Patients: A Systematic Review
by: Pan J, et al.
Published: (2025-01-01)

The Changing Phenotype of Inflammatory Bowel Disease
by: Carthage Moran, et al.
Published: (2016-01-01)

Vedolizumab for inflammatory bowel diseasesI
by: Igor L. Khalif, et al.
Published: (2018-08-01)

Thrombotic Complications in Inflammatory Bowel Disease
by: A. V. Borota, et al.
Published: (2019-05-01)

Fluticasone Propionate in Inflammatory Bowel Disease
by: Marta Carpani de Kaski, et al.
Published: (1990-01-01)

PPARγ in Inflammatory Bowel Disease
by: Vito Annese, et al.
Published: (2012-01-01)

Trends in Inflammatory Bowel Disease Therapy
by: L Sutherland, et al.
Published: (1990-01-01)

Osteomyelitis and Osteonecrosis in Inflammatory Bowel Disease
by: Hugh J Freeman
Published: (1997-01-01)

Thromboelastography in Patients with Inflammatory Bowel Disease
by: Yonghua Shen, et al.
Published: (2020-01-01)

Ocular Complications of Inflammatory Bowel Disease
by: Rana Mady, et al.
Published: (2015-01-01)

Cancer Risk in Inflammatory Bowel Disease
by: Anders M Ekbom
Published: (1995-01-01)